Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Proteins binding her2, nkg2d and cd16

A protein, binding site technology, applied in immunoglobulins, fusion cells, drug combinations, etc., can solve problems such as increased breast cancer metastasis

Pending Publication Date: 2020-03-31
DRAGONFLY THERAPEUTICS INC
View PDF16 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Furthermore, overexpression of HER2 leads to increased breast cancer metastasis

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Proteins binding her2, nkg2d and cd16
  • Proteins binding her2, nkg2d and cd16
  • Proteins binding her2, nkg2d and cd16

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1-N

[0211] Example 1 - NKG2D binding domains bind to NKG2D

[0212] NKG2D binding domain binds to purified recombinant NKG2D

[0213] The nucleic acid sequence of human, mouse or cynomolgus NKG2D extracellular domains (ectodomains) is fused with the nucleic acid sequence encoding human IgG1 Fc domain, and introduced into mammalian cells for expression. After purification, the NKG2D-Fc fusion protein was adsorbed to the wells of a microplate. After blocking the wells with bovine serum albumin to prevent non-specific binding, the NKG2D binding domain was titrated and added to the wells pre-adsorbed with NKG2D-Fc fusion protein. Primary antibody binding was detected using a secondary antibody conjugated to horseradish peroxidase and specifically recognizing human kappa light chain to avoid Fc cross-reactivity. The substrate for horseradish peroxidase, 3,3',5,5'-tetramethylbenzidine (TMB), was added to the wells to visualize the binding signal, measured at 450 nm and corrected at ...

Embodiment 2

[0218] Example 2 - NKG2D Binding Domains Block Natural Ligand Binding to NKG2D

[0219] Competition with ULBP-6

[0220] The recombinant human NKG2D-Fc protein was adsorbed to the wells of a microplate, and the wells were blocked with bovine serum albumin to reduce non-specific binding. A saturating concentration of ULBP-6-His-biotin was added to the wells followed by NKG2D binding domain clones. After 2 hours of incubation, wells were washed and ULBP-6-His-biotin still bound to NKG2D-Fc-coated wells was detected by streptavidin-coupled horseradish peroxidase and TMB substrate. Absorption values ​​were measured at 450 nm and corrected at 540 nm. The specific binding of the NKG2D binding domain to the NKG2D-Fc protein was calculated from the percentage of ULBP-6-His-biotin blocked from binding to the NKG2D-Fc protein in the wells after background subtraction. Positive control antibodies (selected from SEQ ID NO: 45-48) and various NKG2D binding domains blocked ULBP-6 bindi...

Embodiment 3-N

[0225] Example 3 - NKG2D binding domain cloning activates NKG2D

[0226] The nucleic acid sequences of human and mouse NKG2D were fused to the nucleic acid sequence encoding the CD3ζ signaling domain to obtain chimeric antigen receptor (CAR) constructs. The NKG2D-CAR construct was then cloned into a retroviral vector using Gibson assembly and transfected into expi293 cells for retroviral production. EL4 cells were infected with NKG2D-CAR-containing virus together with 8 μg / mL polybrene. 24 hours after infection, the expression level of NKG2D-CAR in the EL4 cells was analyzed by flow cytometry, and clones expressing high levels of NKG2D-CAR on the cell surface were selected.

[0227] To determine whether NKG2D-binding domains activate NKG2D, they were adsorbed to wells of microplates and NKG2D-CAR EL4 cells were incubated on antibody fragment-coated wells in the presence of brefeldin-A and monensin Incubate for 4 hours. Intracellular TNF-[alpha] production, an indicator of N...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Multi-specific binding proteins that bind HER2, the NKG2D receptor, and CD 16 are described, as well as pharmaceutical compositions and therapeutic methods useful for the treatment of cancer.

Description

[0001] Cross References to Related Applications [0002] This application claims the benefit of and priority to U.S. Provisional Patent Application No. 62 / 461,146, filed February 20, 2017, the entire contents of which are hereby incorporated by reference for all purposes. [0003] sequence listing [0004] This application contains a Sequence Listing electronically filed in ASCII format and incorporated herein by reference in its entirety. The ASCII copy generated on February 16, 2018 is named DFY-008PC_SL.txt and is 92,807 bytes in size. technical field [0005] The present invention relates to a multispecific binding protein binding to human epidermal growth factor receptor 2 (HER2 or ErbB2), NKG2D receptor and CD16. Background technique [0006] Despite numerous research attempts and scientific advances in treating cancer that have been reported in the literature, the disease remains a significant health problem. Some of the most frequently diagnosed cancers include pr...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/00A61K39/395C12N5/16C12P21/04C12P21/08C07K16/00
CPCA61K39/395C07K16/00C07K16/283C07K16/2851C07K16/32C07K2317/31C07K2317/52C07K2317/64C07K2317/71C07K2317/73C07K2317/75C07K2317/94C07K2319/30A61P35/00C07K2317/732A61K2039/507C07K2317/622C07K2317/524C07K2317/33C07K2317/53C07K2317/565C07K2317/569
Inventor 格雷戈里·P·常安·F·张威廉·哈尼布拉德利·M·伦德比昂卡·普林茨
Owner DRAGONFLY THERAPEUTICS INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com